[7] Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Onc...
[11]Janjigian Y, Laarhoven H, Rha S, et al. Trastuzumab deruxtecan monotherapy and combinations in patients with advanced/metastatic HER2-positive esophageal, gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03 (DG-03). 2024 ESMO. 1401O. [12]Janjigian Y, Laarhoven H, Rha S...
[14]Shen L, Chen P, Lu J, et al. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma ...
[5]Shen L, Chen P, Lu J, et al. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ...
HER2-positive advanced or metastatic gastric cancer. News release. AstraZeneca. August 13, 2024. Accessed August 13, 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer...
4 Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study[J]. Lancet ...
6. Nina Zhou † , Xiaoyi Guo † , Min Yang, Hua Zhu * , Zhi Yang * . 68 Ga-ZHER2 PET/CT Reveals HER2-positive Metastatic Gastric Cancer with Better Image Quality than 18 F-FDG. Clinical Nuclear Medicine , 2020 , 45(2), e101-e102. ...
3.Tabernero J, Hoff P M, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study[J]. The Lancet Oncology, 2018, 19(10): ...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. ...
[4]Wang DS, Liu ZX, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019 Jul;68(7):1152-1161. [5]Li H, Wang J, Yi Z, et al. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibito...